About 6 results found for searched term "TIGIT" (0.133 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M24851 | Tiragolumab | TIGIT |
| Tiragolumab is an immune checkpoint inhibitor that binds to T-cell immunoglobulin and the structural domain of ITIM (TIGIT), targets TIGIT and has an intact Fc region. Tiragolumab is indicated for use in studies related to solid tumors. | ||
| M25018 | Vibostolimab | TIGIT |
| Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research. | ||
| M25084 | Ociperlimab | TIGIT |
| BGB-A1217 | ||
| Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer. | ||
| M25097 | Domvanalimab | TIGIT |
| AB154 | ||
| Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used in research of cancer. | ||
| M25123 | Tamgiblimab | TIGIT |
| IBI939 | ||
| Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects. | ||
| M54528 | Dargistotug | TIGIT |
| M-6223 | ||
| Dargistotug is a fully human IgG1 monoclonal antibody targeting T-cell immunoglobulin and the ITIM structural domain (TIGIT) that induces an immune response targeting cancer cells by blocking the TIGIT pathway. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
